Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer
Menée à partir des données de 4 essais cliniques incluant 664 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cette étude analyse l'efficacité, du point de vue de la survie globale à 4 ans, et la toxicité du nivolumab en traitement de seconde ligne ou plus
Immune checkpoint inhibitors have become pivotal for the treatment of non-small-cell lung cancer (NSCLC). PD-L1 inhibitors as monotherapy are the standard for second-line therapy (atezolizumab or nivolumab, or pembrolizumab when PD-L1 expression is at least 1%), and even for front-line therapy when PD-L1 expression is at least 50% (pembrolizumab). Front-line administration of standard chemotherapy plus pembrolizumab has been shown to increase survival compared with standard chemotherapy alone, regardless of PD-L1 status and in both squamous and non-squamous histologies. Thus, in less than 5 years, immune checkpoint inhibitors have taken centre stage in metastatic disease treatment.
The Lancet Oncology 2019